197 related articles for article (PubMed ID: 24577942)
1. Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.
Gu L; Talati P; Vogiatzi P; Romero-Weaver AL; Abdulghani J; Liao Z; Leiby B; Hoang DT; Mirtti T; Alanen K; Zinda M; Huszar D; Nevalainen MT
Mol Cancer Ther; 2014 May; 13(5):1246-58. PubMed ID: 24577942
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.
Gu L; Liao Z; Hoang DT; Dagvadorj A; Gupta S; Blackmon S; Ellsworth E; Talati P; Leiby B; Zinda M; Lallas CD; Trabulsi EJ; McCue P; Gomella L; Huszar D; Nevalainen MT
Clin Cancer Res; 2013 Oct; 19(20):5658-74. PubMed ID: 23942095
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo.
Yan S; Li Z; Thiele CJ
Oncotarget; 2013 Mar; 4(3):433-45. PubMed ID: 23531921
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic inhibition of Jak activity inhibits progression of gastrointestinal tumors in mice.
Stuart E; Buchert M; Putoczki T; Thiem S; Farid R; Elzer J; Huszar D; Waring PM; Phesse TJ; Ernst M
Mol Cancer Ther; 2014 Feb; 13(2):468-74. PubMed ID: 24398427
[TBL] [Abstract][Full Text] [Related]
5. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.
Scuto A; Krejci P; Popplewell L; Wu J; Wang Y; Kujawski M; Kowolik C; Xin H; Chen L; Wang Y; Kretzner L; Yu H; Wilcox WR; Yen Y; Forman S; Jove R
Leukemia; 2011 Mar; 25(3):538-50. PubMed ID: 21164517
[TBL] [Abstract][Full Text] [Related]
6. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
[TBL] [Abstract][Full Text] [Related]
7. The ETS factor ESE3/EHF represses IL-6 preventing STAT3 activation and expansion of the prostate cancer stem-like compartment.
Albino D; Civenni G; Rossi S; Mitra A; Catapano CV; Carbone GM
Oncotarget; 2016 Nov; 7(47):76756-76768. PubMed ID: 27732936
[TBL] [Abstract][Full Text] [Related]
8. AZD1480, a JAK inhibitor, inhibits cell growth and survival of colorectal cancer via modulating the JAK2/STAT3 signaling pathway.
Wang SW; Hu J; Guo QH; Zhao Y; Cheng JJ; Zhang DS; Fei Q; Li J; Sun YM
Oncol Rep; 2014 Nov; 32(5):1991-8. PubMed ID: 25216185
[TBL] [Abstract][Full Text] [Related]
9. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.
Hedvat M; Huszar D; Herrmann A; Gozgit JM; Schroeder A; Sheehy A; Buettner R; Proia D; Kowolik CM; Xin H; Armstrong B; Bebernitz G; Weng S; Wang L; Ye M; McEachern K; Chen H; Morosini D; Bell K; Alimzhanov M; Ioannidis S; McCoon P; Cao ZA; Yu H; Jove R; Zinda M
Cancer Cell; 2009 Dec; 16(6):487-97. PubMed ID: 19962667
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480.
Xin H; Herrmann A; Reckamp K; Zhang W; Pal S; Hedvat M; Zhang C; Liang W; Scuto A; Weng S; Morosini D; Cao ZA; Zinda M; Figlin R; Huszar D; Jove R; Yu H
Cancer Res; 2011 Nov; 71(21):6601-10. PubMed ID: 21920898
[TBL] [Abstract][Full Text] [Related]
11. IL-6 stimulation of DNA replication is JAK1/2 mediated in cross-talk with hyperactivated ERK1/2 signaling.
Subotički T; Mitrović Ajtić O; Beleslin-Čokić BB; Bjelica S; Djikić D; Diklić M; Leković D; Gotić M; Santibanez JF; Noguchi CT; Čokić VP
Cell Biol Int; 2019 Feb; 43(2):192-206. PubMed ID: 30571852
[TBL] [Abstract][Full Text] [Related]
12. JAK1/2 Inhibitors AZD1480 and CYT387 Inhibit Canine B-Cell Lymphoma Growth by Increasing Apoptosis and Disrupting Cell Proliferation.
Lu Z; Hong CC; Jark PC; Assumpção ALFV; Bollig N; Kong G; Pan X
J Vet Intern Med; 2017 Nov; 31(6):1804-1815. PubMed ID: 28960447
[TBL] [Abstract][Full Text] [Related]
13. The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis.
Chang Q; Bournazou E; Sansone P; Berishaj M; Gao SP; Daly L; Wels J; Theilen T; Granitto S; Zhang X; Cotari J; Alpaugh ML; de Stanchina E; Manova K; Li M; Bonafe M; Ceccarelli C; Taffurelli M; Santini D; Altan-Bonnet G; Kaplan R; Norton L; Nishimoto N; Huszar D; Lyden D; Bromberg J
Neoplasia; 2013 Jul; 15(7):848-62. PubMed ID: 23814496
[TBL] [Abstract][Full Text] [Related]
14. Comparisons of the efficacy of a Jak1/2 inhibitor (AZD1480) with a VEGF signaling inhibitor (cediranib) and sham treatments in mouse tumors using DCE-MRI, DW-MRI, and histology.
Loveless ME; Lawson D; Collins M; Nadella MV; Reimer C; Huszar D; Halliday J; Waterton JC; Gore JC; Yankeelov TE
Neoplasia; 2012 Jan; 14(1):54-64. PubMed ID: 22355274
[TBL] [Abstract][Full Text] [Related]
15. Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.
Houghton PJ; Kurmasheva RT; Lyalin D; Maris JM; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Keir ST; Wu J; Smith MA
Pediatr Blood Cancer; 2014 Nov; 61(11):1972-9. PubMed ID: 25131802
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of AZD1480 for the treatment of human glioblastoma.
McFarland BC; Ma JY; Langford CP; Gillespie GY; Yu H; Zheng Y; Nozell SE; Huszar D; Benveniste EN
Mol Cancer Ther; 2011 Dec; 10(12):2384-93. PubMed ID: 22027691
[TBL] [Abstract][Full Text] [Related]
17. Stat3 promotes metastatic progression of prostate cancer.
Abdulghani J; Gu L; Dagvadorj A; Lutz J; Leiby B; Bonuccelli G; Lisanti MP; Zellweger T; Alanen K; Mirtti T; Visakorpi T; Bubendorf L; Nevalainen MT
Am J Pathol; 2008 Jun; 172(6):1717-28. PubMed ID: 18483213
[TBL] [Abstract][Full Text] [Related]
18. Discovery and evaluation of Atopaxar hydrobromide, a novel JAK1 and JAK2 inhibitor, selectively induces apoptosis of cancer cells with constitutively activated STAT3.
Sun J; Du Y; Zhang X; Wang Z; Lin Y; Song Q; Wang X; Guo J; Li S; Nan J; Yang J
Invest New Drugs; 2020 Aug; 38(4):1003-1011. PubMed ID: 31612426
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 promotes proliferative vitreoretinopathy by inducing epithelial-mesenchymal transition via the JAK1/STAT3 signaling pathway.
Chen X; Yang W; Deng X; Ye S; Xiao W
Mol Vis; 2020; 26():517-529. PubMed ID: 32818015
[TBL] [Abstract][Full Text] [Related]
20. Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer.
Wen W; Liang W; Wu J; Kowolik CM; Buettner R; Scuto A; Hsieh MY; Hong H; Brown CE; Forman SJ; Horne D; Morgan R; Wakabayashi M; Dellinger TH; Han ES; Yim JH; Jove R
Mol Cancer Ther; 2014 Dec; 13(12):3037-48. PubMed ID: 25319391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]